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analyses in 2 similar populations of patients with noncardio-
embolic ischemic stroke. This first involved 3,635 patients in 
the Outcomes in Patients with TIA and Cerebrovascular dis-
ease (OPTIC) registry (followed for 2 years), with baseline col-
lection of the usual risk factors and 5 socioeconomic vari-
ables (unemployment status, residence in rural area, living in 
fully serviced accommodation, no health-insurance cover-
age, and low educational level). The second involved pa-
tients in the PERFORM trial ( n = 19,100 followed up for 2 
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 Abstract 
 Background: Stroke is largely preventable, and therefore, a 
better understanding of risk factors is an essential step in re-
ducing the population stroke rate and resulting disease bur-
den in Arab countries.  Summary: We performed 2 separate 
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years), with baseline collection of the usual risk factors and 1 
socioeconomic variable (low educational level). The primary 
outcome was a composite of nonfatal stroke, nonfatal myo-
cardial infarction, or cardiovascular death. Stroke risk factors 
were more prevalent in patients in Arab countries. The inci-
dence of major cardiovascular events (MACE; age- and gen-
der-adjusted) was higher in Arab countries (OPTIC, 18.5 vs. 
13.3%; PERFORM, 18.4 vs. 9.7%; both  p  ≤ 0.0001). These re-
sults remained significant after adjustment on risk factors 
and were attenuated in OPTIC after further adjustment on 
socioeconomic variables (hazard ratio 1.24; 95% CI 0.98–
1.55;  p  = 0.07).  Key Messages: Patients with ischemic stroke 
living in Arab countries had a lower mean socioeconomic 
status, a much higher prevalence of diabetes mellitus, and a 
higher rate of MACE compared with patients from non-Arab 
countries. This finding is partly explained by a higher preva-
lence of risk factors and also by a high prevalence of poverty 
and low educational level.  © 2017 S. Karger AG, Basel 
 Atherothrombosis is a diffuse progressive process that 
manifests in multiple vascular beds; it starts early during 
childhood and progresses asymptomatically through 
adult life, resulting in nearly all cases of acute coronary 
syndrome and peripheral artery disease, and many cases 
of stroke  [1] . Globally, stroke is the second leading cause 
of death  [2] and over 80% of all stroke deaths worldwide 
occur in developing countries  [3] . With epidemiology 
transition in low- and middle-income countries, more fo-
cus is projected on the control of atherosclerotic risk fac-
tors, but socioeconomic variables also play a major role 
in contributing to the risk of stroke  [4] .
 Earlier on, the incidence of stroke was found to be the 
greatest in high-income countries, but its incidence in 
low- and middle-income countries now exceeds that of 
high-income countries by 20%  [5, 6] . As stroke is largely 
preventable, knowledge of risk factors is an essential step 
in reducing the population stroke rate and resulting dis-
ease burden  [7] . Many studies have addressed the speci-
ficities of risk factors in Asian  countries, or across eth-
nicities, including black, Hispanic, and Asian ancestry, 
but no large studies have addressed the specificities of 
stroke risk factors and outcomes in Arab countries. We, 
therefore, performed parallel analyses of data from 2 in-
ternational prospective studies that included similar pop-
ulations of ischemic stroke patients, to compare risk fac-
tors (including socioeconomic factors) and 2-year out-
comes between patients living in Arab (Middle East and 
North Africa) and non-Arab countries.
 Methods 
 Data Source and Study Population 
 We first analyzed data from the Outcomes in Patients with TIA 
(transient ischemic attack) and Cerebrovascular disease (OPTIC) 
registry  [4] . Briefly, the OPTIC registry enrolled 3,635 patients 
(January 2007–December 2008) age  ≥ 45 years from 17 low- and 
middle-income countries across Latin America (Brazil, Chile, 
 Colombia, Dominican Republic, Ecuador, Mexico, Peru, Venezu-
ela), the Middle East (Egypt, Iran, Jordan, Lebanon, Saudi Arabia), 
North Africa (Algeria, Morocco, Tunisia), and South Africa. Of 
these patients, 148 had no follow-up information, 130 did not re-
turn after the baseline visit, and 18 withdrew their consent to par-
ticipate for other reasons, leaving a study population of 3,487 pa-
tients. OPTIC was designed to provide 2-year clinical follow-up. 
Patients were followed every 6 ± 1 months for key outcome events, 
medication use, and change in employment status. The group 
from the Arab region included patients enrolled in countries in the 
Middle East and North Africa, except Iran.
 We also analyzed data from patients enrolled in the Prevention 
of Cerebrovascular and Cardiovascular Events of Ischemic Origin 
with Terutroban in the Patients with a History of Ischemic Stroke 
or Transient Ischemic Attack (PERFORM) trial, an international 
randomized controlled trial, designed to compare terutroban with 
aspirin in the prevention of cerebral and cardiovascular ischemic 
events in patients ( ≥ 55 years) with a noncardioembolic ischemic 
stroke ( ≤ 3 months) or a TIA ( ≤ 8 days)  [8] . In short, PERFORM 
enrolled 19,100 subjects (February 2006–April 2008) from 802 
sites in 46 countries over 5 continents. Follow-up visits were per-
formed at 1, 3, and 6 months, and every 6 months thereafter; the 
minimum follow-up duration was 2 years. The group from the 
Arab region comprised patients enrolled in Morocco and Tunisia.
 All participants provided written informed consent. We used 
the World Bank classification for the definition of Arab countries.
 Evaluations 
 The baseline data collected for each patient included demo-
graphic characteristics, medical history, and medication use. In the 
OPTIC registry, socioeconomic profile (living alone, residence in 
rural area, living in fully serviced accommodation [i.e., house/
apartment with electricity, toilet, water supply], employment sta-
tus, health insurance coverage, low education level [i.e., <2 years 
of schooling]) was also recorded. Education level was the only so-
cioeconomic information collected in the PERFORM trial. Infor-
mation, which was recorded at baseline and at follow-up along 
with key outcome events using a standardized case report form, 
was entered into a central database.
 The primary study outcome was a composite of nonfatal stroke, 
nonfatal myocardial infarction, or cardiovascular death. Second-
ary outcomes were myocardial infarction and stroke separately (fa-
tal or nonfatal). Events were not adjudicated in the OPTIC registry, 
whereas all events were adjudicated by a blinded endpoint com-
mittee in the PERFORM trial.
 Statistical Analysis 
 Categorical variables are expressed as means ± SD in the case of 
normal distribution or median (interquartile range [IQR]) other-
wise. Qualitative variables are expressed as counts (percentage). 
Normality of distributions was assessed graphically and by using the 
Shapiro–Wilk test. All analyses were conducted separately in the 
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OPTIC and PERFORM cohorts using the same analysis strategy. In 
both studies, patients were classified into 2 groups based on their 
country of origin (i.e., whether they resided in a Arab or a non-Arab 
country). Baseline characteristics (demographics, medical history, 
examination findings, socioeconomic factors, medication use) were 
compared between the 2 groups after adjustment on age and gender 
using linear regression models for quantitative variables and logistic 
regression models for binary variables. Owing to skewed distribu-
tions for triglycerides, creatinine, and glucose concentrations, linear 
regression analysis was performed using log-transformed values.
 We compared the 2-year event rate (primary and secondary 
outcomes) between the 2 groups using Cox proportional hazard 
models adjusted for age and gender (model 1). Adjusted event 
curves and rates were calculated using the corrected-group prog-
nosis method  [9] ; adjustment for age was made using the quartile 
values. For a given outcome, deaths that were not included in the 
endpoint were treated as censoring events. Events that occurred 
after the 2-year follow-up were not included. Using non-Arab 
countries as the reference, we derived, from Cox proportional haz-
ard models, hazard ratios (HRs) as effect size measures with their 
95% CIs. The proportional hazard assumptions were checked us-
ing the log–log survival plots and by introducing a time-dependent 
variable into models.
 Further multivariable Cox’s regression models were performed 
to adjust the comparison in outcomes between the 2 study groups on 
traditional cardiovascular risk factors regarding the high disparities 
in their distribution between the study groups whatever the cohort. 
Similarly, regarding our previous OPTIC publication  [10] showing 
an independent association of socioeconomics factors with cardio-
vascular risk, a multivariable model was performed by including so-
cioeconomics factors as covariables. Thus, the following additional 
models were considered, which included model 1 variables plus hy-
pertension, dyslipidemia, and smoking (model 2); model 2 variables 
plus body mass index and diabetes (model 3); and model 3 variables 
plus socioeconomic data (model 4). We also included these factors 
as a quantitative variable by calculating the total number, and evalu-
ated its effect on the primary outcome across the 2 groups.
 Finally, we combined the 2 datasets and performed the same 
analysis. All Cox’s regression models were stratified on study.
 Statistical testing was done, and a 2-tailed α-level of 0.05 was 
considered significant. Data were analyzed using SAS software ver-
sion 9.3 (SAS Institute, Cary, NC, USA).
 Results 
 Of the 3,487 patients in the OPTIC registry, 1,669 (47.9%) 
were from Arab countries and 1,818 from non-Arab coun-
tries; patients were followed for a median of 24 months 
(IQR 3–34 months). Of the 19,100 patients included in the 
PERFORM trial, 268 (1.4%) were from Arab countries; the 
median follow-up was 29 months (IQR 24–34).
 Baseline Characteristics 
 Table 1 shows the main baseline demographic and clin-
ical history characteristics of patients in the OPTIC regis-
try and the PERFORM trial. In both databases, the biggest 
difference was observed for diabetes. Patients from Arab 
countries had a higher prevalence of diabetes in both the 
OPTIC registry (43.9 vs. 29.3%,  p  < 0.0001) and the 
 PERFORM trial (50.0 vs. 27.4%,  p  < 0.0001). There were 
also significant differences in socioeconomic characteris-
tics between Arab and non-Arab countries ( Table 2 ). On-
line supplementary Table 1 (for all online suppl. material, 
see www.karger.com/doi/10.1159/000454776) shows high 
disparities in medication use at baseline across the 2 
groups. The use of antiplatelet agents was more common 
at baseline in patients living in Arab countries. However, 
despite the high use of antiplatelet agents in primary and 
secondary prevention, and the good adherence to treat-
ment during the study period, stroke continued to strike 
among the Arab region.
 Two-Year Vascular Event Rates 
 In the OPTIC registry, 516 patients had at least 1 major 
cardiovascular event (MACE; nonfatal stroke, nonfatal 
myocardial infarction, or cardiovascular death) during 
the 2-year follow-up, with an event rate of 15.6% (95% CI 
14.4–16.9). The rate of MACEs for patients living in Arab 
countries was higher than in those living in non-Arab 
countries (age- and gender-adjusted HR 1.31; 95% CI 
1.08–1.58;  p  = 0.006;  Fig. 1 a). After adjustments on age, 
gender, hypertension, dyslipidemia, and current smoking 
(model 2), the results remained significant (HR 1.33; 95% 
CI 1.09–1.63;  p  = 0.005). When body mass index and dia-
betes were added to the model (model 3), the results re-
mained unchanged (HR 1.32; 95% CI 1.07–1.63;  p  = 
0.009). However, after adjusting for all variables plus so-
cioeconomic variables, the association was no longer sig-
nificant (HR 1.24; 95% CI 0.98–1.55;  p  = 0.07). When an-
alyzing the outcome as a function of the number of socio-
economic factors, there were no changes in association 
between primary events and the 2 groups (adjusted HR 
1.15; 95% CI 0.93–1.43;  p = 0.20). Patients with low socio-
economic factors were more frequently from Arab coun-
tries ( Fig. 2 a). In both Arab and non-Arab countries, the 
2-year risk of MACEs increased with the number of low 
socioeconomic factors (age- and gender-adjusted  p value 
for trend <0.0001 for both;  Fig. 2 b). For Arab countries, 
the rate ranged from 15.8% for patients with no low so-
cioeconomic factors to 56.9% in those with  ≥ 5 factors.
 In the PERFORM trial, 1,833 patients had a MACE 
during the 2-year follow-up. As in the OPTIC registry, the 
2-year risk of vascular events was higher in patients from 
Arab countries (age- and gender-adjusted HR 1.97; 95% 
CI 1.46–2.66;  p  < 0.0001;  Fig. 1 b). The same results were 
obtained after multiple adjustments ( Table 3 ). These re-
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Table 1.  Baseline characteristics of patients living in Arab and non-Arab countries in the OPTIC registry and the PERFORM trial
OPTIC registry  PERFORM trial
non-Arab countries
(n = 1,818)
Arab countries
(n = 1,669)
p value* non-Arab c ountries
(n = 18,832)
Arab countries
(n = 268)
p value*
Age, years, mean ± SD 66.3±11.2 64.1±10.4 <0.0001 67.3±7.9 66.2±7.2 0.03
Men 950 (52.3) 1,028 (61.6) <0.0001 11,807 (62.7) 143 (53.4) 0.0005
Medical history
Congestive heart failure 52 (2.9) 68 (4.2) 0.008 872 (4.6) 0 (0.0) –
Coronary artery disease 199 (11.0) 244 (14.8) 0.002 4,098 (21.8) 21 (7.8) <0.0001
Diabetes 533 (29.3) 733 (43.9) <0.0001 5,165 (27.4) 134 (50.0) <0.0001
Dyslipidemia 1,395 (76.7) 1,161 (69.6) <0.0001 11,365 (60.4) 92 (34.3) <0.0001
Hypertension 1,519 (83.6) 1,360 (81.5) 0.15 15,771 (83.7) 193 (72.0) <0.0001
Peripheral artery disease 158 (9.0) 104 (6.6) 0.006 735 (3.9) 4 (1.5) 0.07
TIA 367 (20.5) 417 (25.8) 0.0004 1,432 (7.6) 6 (2.2) 0.002
Current smoking 270 (15.3) 452 (28.1) <0.0001 5,019 (26.7) 55 (20.5) 0.03
Presentation characteristics
BMI, kg/m2, mean ± SD 26.8±4.5 28.1±5.2 <0.0001 27.1±4.3 26.4±4.9 0.003
Systolic BP, mm Hg, mean ± SD 142±24.41 147±24.6 <0.0001 137±15.6 138±14.4 0.32
Diastolic BP, mm Hg, mean ± SD 84±13.3 86±13.5 0.002 80±8.5 78±9.2 <0.0001
Laboratory findings
Total cholesterol, mg/dL, mean ± SD 194±49.3 200±55.6 0.002 180±44.5 184±45.1 0.45
LDL-cholesterol, mg/dL, mean ± SD 118±41.9 125±41.8 0.001 108±37.9 116±38.4 0.009
HDL-cholesterol, mg/dL, mean ± SD 44±14.6 46±19.6 0.004 49±13.5 43±11.0 <0.0001
Triglycerides, mg/dL, median (IQR)† 138 (101.9–195.8) 140 (99.9–195.8) 0.64 128 (95.6–174.3) 126 (98.2–165.5) 0.22
Triglycerides >200 mg/dL 259 (14.3) 286 (17.1) 0.02 2,874 (15.3) 47 (13.6) 0.03
Creatinine, mg/L, median (IQR)† 0.90 (0.80–1.10) 1.00 (0.80–1.20) <0.0001 0.92 (0.78–1.06) 0.86 (0.70–1.07) 0.77
Glucose, mg/dL, median (IQR)† 104.0 (92.0–128.0) 119.0 (98.0–178.4) <0.0001 102.7 (93.7–120.7) 118.9 (99.1–178.4) <0.0001
 Data are number (%) unless otherwise indicated.
TIA, transient ischemic attack; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low- density 
lipoprotein. Percentage are based on available data.
* Age and gender–adjusted p value.
† Logarithmic values.
Table 2.  Socioeconomic profile of patients living in Arab and non-Arab countries in the OPTIC registry and the PERFORM trial
OPTIC registry  PERFORM trial
non-Arab countries
(n = 1,818)
Arab countries
(n = 1,669)
p value* non-Ara b countries
(n = 18,832)
Arab countries
(n = 268)
p value*
Living alone 194 (10.8) 98 (5.9) <0.0001 NA NA
Living in rural area 130 (7.2) 310 (19.0) <0.0001 NA NA
Living in fully serviced 
house/apartment 1,682 (94.0) 1,488 (90.8) <0.0001 NA NA
Unemployed† 484 (26.6) 600 (36.0) <0.0001 NA NA
No health insurance coverage 266 (14.7) 533 (32.0) <0.0001 NA NA
Low educational level‡ 210 (11.6) 692 (42.5) <0.0001 2,611 (13.9) 232 (67.0) <0.0001
 Data are number (%).
* Age- and gender-adjusted p value. 
† Excluding social pensioner on disability grant or old-age pensioner.
‡ The threshold was <2 years of schooling in OPTIC and ≤4 years of schooling in PERFORM. 
NA indicates not available.
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sults are partly explained by a large difference in the rate 
of vascular deaths between the 2 groups, which was 5 
times higher in patients living in Arab countries. This 
finding should, however, be interpreted with caution due 
to the low proportion of patients living in Arab countries 
enrolled in the PERFORM trial (1.4%).
 In the combined analysis, we found a significant asso-
ciation between the 2 groups regarding the risk of MACE, 
fatal, or nonfatal stroke and cardiovascular death in all the 
models tested ( Table 3 ). The risk was higher among pa-
tients living in Arab countries as against those not living 
in Arab countries.
 Discussion 
 The large, multinational OPTIC registry and PERFORM 
trial provided an opportunity to evaluate stroke risk factors 
in patients from Arab countries. We found a trend for a 
higher frequency of the usual risk factors for stroke and ev-
idence of inadequately managed diabetes mellitus, hyper-
tension, and tobacco smoking in patients from Arab coun-
tries. Furthermore, stroke appeared to occur at a younger 
age in patients living in Arab countries, as reported previ-
ously  [11–13] , indicating an opportunity to prevent the oc-
currence of premature stroke. Another important finding 
from our analysis was that after adjustment on socioeco-
nomic variables, the differences between patients living in 
Arab and non-Arab countries were attenuated in the  OPTIC 
registry, indicating that these socioeconomic variables sig-
nificantly affect stroke risk in these countries. Our findings 
suggest that improvements in healthcare systems and edu-
cational level, and provision of fully serviced accommoda-
tion and health insurance cover in Arab countries may help 
to reduce the incidence of stroke.
 In our study, the prevalence of hypertension was high-
er in non-Arab countries than in Arab countries. One 
probable reason for this is the older mean age of patients 
with stroke in non-Arab countries, since blood pressure 
tends to increase with age  [12] . Additionally, hyperten-
sion tends to occur more frequently in Arab women com-
pared with Arab men  [13] . Finally, limited access to 
healthcare services and lack of preventive care may con-
tribute to low hypertension awareness and high hyper-
tension at the time of admission and antihypertensive 
medications at follow-up in patients living in Arab coun-
tries (online suppl. Table 2).
 Diabetes, as an independent risk factor for stroke, 
was highly prevalent in Arab countries. The prevalence 
was 43.9% in the OPTIC registry and 50.0% in  PERFORM 
trial, as compared with 29.3 and 27.4%, respectively, in 
non-Arab countries. Diabetes is also reported to be 
more frequent in patients living in urban areas  [14] . An 
estimated 9.1% of the population from the Middle East-
ern/North African region was estimated to have type 
2 diabetes (32.8 million people) in 2011, and this epi-
demic is projected to reach 60 million in 2030. Many 
factors, from changes in physical activity and nutrition 
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patterns  [15] to genetic predisposition  [16] , are likely to 
contribute to the high prevalence of diabetes and over-
weight/obesity in this region. Consequently, one expects 
a high correlation between stroke in Arab regions and 
diabetes.
 While rates of smoking have increased in most Arab 
countries, they have decreased in most western countries 
 [17] . The overall percentage of cigarette smoking (cur-
rent) was higher for stroke patients in the Arab region 
compared to non-Arab countries in the OPTIC registry 
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(28.1 vs. 15.3%, respectively). In addition, tobacco use in 
many Arab countries is not limited to cigarettes. Water-
pipe smoking is growing in popularity among the youth 
in the Middle East and North Africa, and even worldwide 
 [18] . Another issue is smoking in women, which is often 
construed as a vice that undermines the social standing of 
the family in many Muslim communities  [19] . As a result, 
the prevalence of smoking in the Arab region is probably 
underestimated in our study.
 Antiplatelet agents were used in 95% of [0]patients liv-
ing in Arab countries as compared to 91% in other  OPTIC 
registry countries. However, despite the high use of anti-
platelet agents in primary and secondary prevention, and 
the good adherence to treatment during the study period, 
occurrence of stroke continue to strike among Arab re-
gion.
 In the OPTIC registry, stroke survivors in Arab coun-
tries lived more frequently in rural areas with their fami-
lies, they were also less likely to have health insurance 
cover or to achieve a high educational level than patients 
in non-Arab countries. This presents another barrier to 
stroke prevention because higher educational level cor-
relates with increased awareness of stroke vascular risk 
factors  [20] , and particularly about lifestyle choices. This 
study was limited by the fact that we were unable to ana-
lyze the patients according to their ethnicity. Second, this 
study may not be entirely representative of the Arab 
countries, which exhibit variations in educational level, 
economic factors, and health improvements.
 In conclusion, patients with ischemic stroke living in 
Arab countries had a lower mean socioeconomic status, 
a much higher prevalence of diabetes mellitus, and a 
higher risk of recurrent vascular events compared with 
patients from non-Arab countries. These differences 
were markedly attenuated after adjustment on socioeco-
nomic variables. Thus, there is an opportunity for major 
improvements in the prevention of stroke and cardiovas-
cular events in these countries, at the health policy level 
as well as with primary prevention measures, including 
health policy for smoking cessation and lifestyle changes 
to modify the metabolic profile of the population and to 
lower blood pressure. There is, however, an urgent need 
for comprehensive studies on the role of low socioeco-
nomic status and its contribution to the occurrence of 
stroke and cardiovascular events in Arab countries.
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